An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.
The epidermal growth factor receptor (EGFR) is overexpressed in approximately 90% of head and neck squamous cell carcinomas (HNSCC), and molecularly targeted therapy against the EGFR with the monoclonal antibody cetuximab modestly increases overall survival in head and neck cancer patients. We hypot...
Main Authors: | Emily K Kleczko, Jihye Kim, Stephen B Keysar, Lydia R Heasley, Justin R Eagles, Matthew Simon, Marianne E Marshall, Katherine R Singleton, Antonio Jimeno, Aik-Choon Tan, Lynn E Heasley |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4422719?pdf=render |
Similar Items
-
Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities
by: Emily K. Kleczko, et al.
Published: (2018-02-01) -
TGF-β-activated kinase-1: New insights into the mechanism of TGF-β signaling and kidney disease
by: Sung Il Kim, et al.
Published: (2012-06-01) -
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
by: Kathryn E Ware, et al.
Published: (2010-11-01) -
TGF-β1 Augments the Apical Membrane Abundance of Lemur Tyrosine Kinase 2 to Inhibit CFTR-Mediated Chloride Transport in Human Bronchial Epithelia
by: Daniel F. Cruz, et al.
Published: (2020-02-01) -
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
by: Natalia J. Gurule, et al.
Published: (2021-05-01)